Haloperidol tablets - Approved for Marketing
On December 17, 2025, our company's haloperidol tablets were approved for marketing. The product was approved according to the new registration classification of chemical drugs and was deemed to have passed the consistency evaluation, making it the fourth drug in China to have passed the evaluation. This drug belongs to the national basic medicine and Class A medical insurance drugs.
Haloperidol is a classic antipsychotic drug belonging to the butyrylbenzenes class. Its antipsychotic effects are related to its ability to block dopamine receptors in the brain and promote dopamine conversion. It has good anti hallucination and anti agitation effects, with strong anti pyramidal dopamine and antiemetic effects. However, its sedative and anti alpha adrenergic receptor and cholinergic receptor effects are relatively weak.
